Table 2.
Objective response to treatment.
| CR | PR | SD | PD | ORR | Total | P value | |
|---|---|---|---|---|---|---|---|
| (A) ORR of BRAFm and BRAFwt patients | |||||||
| BRAF-mutated | 12 (14.6%) | 37 (45.1) | 11 (13.4) | 22 (26.8) | 52 (63.4) | 82 | 0.42 |
| BRAF-wt | 3 (7.9%) | 14 (42.1) | 6 (15.8) | 15 (39.5) | 31 (54.8) | 38 | |
| total | 15 | 51 | 17 | 37 | 84 | 120 | |
| (B) ORR of BRAFm patients treated with immunotherapy and targeted therapy | |||||||
| IT | 4 (12.5%) | 10 (31.3%) | 7 (21.9%) | 11 (34.4%) | 14(43.8) | 32 | 0.04 |
| TT | 8 (16.0%) | 27 (54.0%) | 4 (8.0%) | 11 (22.0%) | 35 (70.0) | 50 | |
| total | 12 | 37 | 11 | 22 | 49 | 82 | |
| (C) ORR of BRAFm and BRAFwt patients treated with immunotherapy | |||||||
| BRAF-mutated | 4 (12.5) | 10 (31.3) | 7 (21.9) | 11 (34.4) | 14 (43.8) | 32 | 0.80 |
| BRAF-wt | 8 (13.8) | 19 (32.8) | 11 (19.0) | 20 (34.5) | 27 (46.6) | 58 | |
| total | 12 | 29 | 18 | 31 | 41 | 90 | |
| (D) ORR of patients treated with immunotherapy that received combination therapy and monotherapy | |||||||
| Combination therapy | 12 (18.8%) | 24 (37.5%) | 7 (10.9%) | 21 (32.8%) | 36(56.3%) | 64 | 0.93 |
| Monotherapy | 4(15.4%) | 10(38.5%) | 4(15.4%) | 8(30.8%) | 14(53.8%) | 26 | |
| total | 16 | 34 | 11 | 29 | 31 | 90 | |
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; IT, immunotherapy; TT, targeted therapy. The bold value is a significative value in the analysis.